Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Indivior PLC Ordinary Shares (INDV)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2025: INDV (5-star) is a REGULAR-BUY. BUY since 100 days. Simulated Profits (97.84%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $29.17
1 Year Target Price $29.17
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 110.96% | Avg. Invested days 44 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.87B USD | Price to earnings Ratio 28.36 | 1Y Target Price 29.17 |
Price to earnings Ratio 28.36 | 1Y Target Price 29.17 | ||
Volume (30-day avg) 7 | Beta 1.06 | 52 Weeks Range 7.33 - 25.10 | Updated Date 09/18/2025 |
52 Weeks Range 7.33 - 25.10 | Updated Date 09/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.52% | Operating Margin (TTM) 23.51% |
Management Effectiveness
Return on Assets (TTM) 13.14% | Return on Equity (TTM) 12.2% |
Valuation
Trailing PE 28.36 | Forward PE 11.99 | Enterprise Value 2719467369 | Price to Sales(TTM) 2.44 |
Enterprise Value 2719467369 | Price to Sales(TTM) 2.44 | ||
Enterprise Value to Revenue 2.32 | Enterprise Value to EBITDA 10.42 | Shares Outstanding 124769820 | Shares Floating 91135620 |
Shares Outstanding 124769820 | Shares Floating 91135620 | ||
Percent Insiders 3.88 | Percent Institutions 88.16 |
Upturn AI SWOT
Indivior PLC Ordinary Shares
Company Overview
History and Background
Indivior PLC was formed in 2014 as a spin-off from Reckitt Benckiser. It focuses on treatments for addiction and mental health disorders, particularly opioid use disorder.
Core Business Areas
- Opioid Dependence Treatment: Development, manufacturing, and commercialization of medications used to treat opioid dependence, with a focus on buprenorphine-based therapies.
- Alcohol Dependence Treatment: Indivior also has a portfolio of medicines indicated for treatment of Alcohol Use Disorder
Leadership and Structure
The company has a Board of Directors and an executive leadership team headed by the CEO. The structure is organized by function (e.g., R&D, commercial, finance).
Top Products and Market Share
Key Offerings
- Suboxone: A sublingual film containing buprenorphine and naloxone for opioid dependence treatment. Suboxone used to hold about 50% of the market for buprenorphine prescriptions but has dramatically decreased since generics entered. Competitors include generic buprenorphine/naloxone products and Sublocade.
- Sublocade: A buprenorphine extended-release injectable suspension for monthly administration in adults with opioid use disorder. Sublocade now holds a majority share of the buprenorphine market, surpassing Suboxone. Competitors are mostly the daily Suboxone or generic pills. Also, Brixadi.
- Perseris: Risperidone extended-release injectable suspension for schizophrenia treatment. It generates less revenue than Suboxone and Sublocade. Competitors are other long-acting injectable antipsychotics.
Market Dynamics
Industry Overview
The addiction treatment market is growing, driven by increasing rates of opioid and other substance use disorders. There is increasing demand for medication-assisted treatment (MAT).
Positioning
Indivior is a key player in the opioid dependence treatment market, with a strong presence in buprenorphine-based therapies, especially Sublocade due to convenience factor of just a monthly injection rather than a daily pill.
Total Addressable Market (TAM)
The total addressable market for opioid use disorder treatments is estimated to be in the billions of dollars. Indivior is positioned to capture a significant portion of this market with Sublocade and other pipeline products.
Upturn SWOT Analysis
Strengths
- Established presence in opioid dependence treatment
- Strong intellectual property protection for key products
- Innovative injectable formulations (Sublocade)
- Experienced management team
Weaknesses
- Reliance on a limited number of key products
- Exposure to generic competition for older products (Suboxone)
- Litigation risks related to past marketing practices
- Potential for regulatory scrutiny
Opportunities
- Expanding the use of MAT in underserved populations
- Developing new formulations and delivery systems
- Acquiring or partnering with companies with complementary technologies
- Expanding into new markets (geographically)
Threats
- Increased competition from generic manufacturers
- Changes in regulatory policies
- Pricing pressures from payers
- Negative publicity related to the opioid crisis
Competitors and Market Share
Key Competitors
- OTCQX:BTZI
- TEVA
- MYL
Competitive Landscape
Indivior has a strong competitive position in the market for opioid dependence treatments, particularly with Sublocade, but faces increasing competition from generic manufacturers and other branded products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been mixed, with strong growth in Sublocade sales offset by declines in Suboxone sales.
Future Projections: Analyst estimates vary but generally project continued growth driven by Sublocade and other pipeline products.
Recent Initiatives: Recent initiatives include expanding the sales force, developing new formulations, and pursuing strategic partnerships.
Summary
Indivior is a key player in the opioid dependence treatment market, particularly with Sublocade driving revenue growth. While facing competition from generics and potential litigation risks, the company has a strong innovative product offering and growth potential. Future success hinges on expanding its market share, navigating regulatory hurdles, and effectively managing competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indivior PLC Ordinary Shares
Exchange NASDAQ | Headquaters North Chesterfield, VA, United States | ||
IPO Launch date 2014-12-29 | CEO & Director Mr. Joseph J. Ciaffoni | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1000 | Website https://www.indivior.com |
Full time employees 1000 | Website https://www.indivior.com | ||
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.